Intensity Therapeutics, Inc. (INTS) SEC Filings https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/rss Intensity Therapeutics, Inc. (INTS) - All SEC Filings en-us https://d1io3yog0oux5.cloudfront.net/intensitytherapeutics/files/theme/images/logo-sm.png Intensity Therapeutics, Inc. Logo Equisolve Investor Relations Suite <![CDATA[8-K - Current report]]> https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000047/0001567264-26-000047.pdf Thu, 07 May 26 16:18:32 -0400 https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000047/0001567264-26-000047.pdf <![CDATA[10-Q - Quarterly report [Sections 13 or 15(d)]]]> https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000046/0001567264-26-000046.pdf Thu, 07 May 26 16:02:29 -0400 https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000046/0001567264-26-000046.pdf <![CDATA[ARS - Annual Report to Security Holders]]> https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000037/0001567264-26-000037.pdf Thu, 30 Apr 26 16:13:12 -0400 https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000037/0001567264-26-000037.pdf <![CDATA[DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material]]> https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000036/0001567264-26-000036.pdf Thu, 30 Apr 26 16:13:02 -0400 https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000036/0001567264-26-000036.pdf <![CDATA[DEF 14A - Definitive proxy statements]]> https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000035/0001567264-26-000035.pdf Thu, 30 Apr 26 16:07:48 -0400 https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000035/0001567264-26-000035.pdf <![CDATA[4 - Statement of changes in beneficial ownership of securities]]> https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001238705-26-000005/0001238705-26-000005.pdf Mon, 30 Mar 26 17:30:19 -0400 https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001238705-26-000005/0001238705-26-000005.pdf <![CDATA[8-K - Current report]]> https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000025/0001567264-26-000025.pdf Fri, 27 Mar 26 16:20:39 -0400 https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000025/0001567264-26-000025.pdf <![CDATA[10-K - Annual report [Section 13 and 15(d), not S-K Item 405]]]> https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000024/0001567264-26-000024.pdf Fri, 27 Mar 26 16:02:49 -0400 https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000024/0001567264-26-000024.pdf <![CDATA[8-K - Current report]]> https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000021/0001567264-26-000021.pdf Mon, 23 Mar 26 16:02:30 -0400 https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000021/0001567264-26-000021.pdf <![CDATA[424B5 - Prospectus [Rule 424(b)(5)]]]> https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000020/0001567264-26-000020.pdf Mon, 23 Mar 26 16:01:08 -0400 https://ir.intensitytherapeutics.com/sec-filings/all-sec-filings/content/0001567264-26-000020/0001567264-26-000020.pdf